Breakthrough Award Levels 1 & 2 – HT9425-23-BCRP-BTA12 – Letter of Intent due 28 March 2023
- Funding Level 1 – up to USD$450,000 over 3 years
- Funding Level 1 with Partnering PI option – up to USD$750,000 over 3 years
- Funding Level 2 – up to USD$1M over 3years
- supports promising research with high potential to lead or make breakthroughs in breast cancer
- Funding Level 1 – innovative, high-risk/high-reward research in the earliest stages of development. Preliminary data not required.
- Funding Level 2 – research already supported by substantial preliminary or published data & strongly validates clinical translation
- Funding Level 2 – Population and Prevention studies – investigate why certain human patient populations differ in cancer risk or clinical prognosis
- Clinical trials not allowed
Breakthrough Award Level 3 – HT9425-23-BCRP-BTA3 – pre-application due 29 March 2023
- Up to USD$4M over 4 years
- with Partnering PI Option – up to USD$5M over 4 years
- Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
- Advanced translational studies with a high degree of project readiness
- must include two or more breast cancer advocates on the research team.
- Clinical trials are allowed
Breakthrough Award Level 4 – HT9425-23-BCRP-BTA4 – Pre-application due 29 March 2023
- up to USD$15M over 4 years
- Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
- Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer.
- must include two or more breast cancer advocates on the research team.
- Human clinical trials are required.
Innovator Award – HT9425-23-BCRP-INNOV – Pre-application due 29 March 2023
- Up to USD$7M over 4 years
- Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.
- Associate Professor or above
- Experience in breast cancer research not required
- must include two or more breast cancer advocates on the research team
- Clinical trials are allowed.
Clinical Research Extension Award – HT9425-23-BCRP-CREA2 – Letter of Intent due 28 March 2023
- up to USD$5M over 4 years
- with partnering PI option – up to USD4M over 4 years
- supports research that extends data collection, follow-up and analysis of breast cancer clinical research studies
- aims to increase clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.
- may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.
- must include two or more breast cancer advocates on the research team
- clinical trials not allowed
Supporting Documents:
